Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Exelixis, Inc. is an oncology-focused biopharmaceutical company developing targeted cancer therapies, primarily through its flagship molecule cabozantinib. Its core business includes marketing approved treatments for kidney, thyroid, liver, and other cancers, alongside a robust pipeline of investigational small molecules and biotherapeutics. The company leverages strategic collaborations and licensing to expand its portfolio, aiming to improve cancer patient outcomes worldwide.
This description was generated via AI from an annual report. Updated about 1 year ago.